Suggested remit: To appraise the clinical and cost effectiveness of evinacumab within its marketing authorisation for treating homozygous familial hypercholesterolaemia in people aged 12 and over.
 
Status Awaiting development
Decision None selected
Process STA 2018
ID number 2704

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
14 December 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over. Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
14 September 2020 (14:00) Scoping workshop
16 July 2020 - 13 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual